BFC
MYGN icon

Bedel Financial Consulting’s Myriad Genetics MYGN Stock Holding History

Bedel Financial Consulting’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22
Closed -$1K – 1030
2021
Q4 		$1K Hold
22
– – ﹤0.01% 958
2021
Q3 		$1K Hold
22
– – ﹤0.01% 945
2021
Q2 		$1K Hold
22
– – ﹤0.01% 935
2021
Q1 		$1K Hold
22
– – ﹤0.01% 900
2020
Q4 		$0 Hold
22
– – ﹤0.01% 861
2020
Q3 		$0 Hold
22
– – ﹤0.01% 840
2020
Q2 		$0 Hold
22
– – ﹤0.01% 882
2020
Q1 		$0 Hold
22
– – ﹤0.01% 881
2019
Q4 		$1K Hold
22
– – ﹤0.01% 736
2019
Q3 		$1K Buy
+22
New +$641 ﹤0.01% 716

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bedel Financial Consulting's MYGN Position: Q1 2022 in Review

Bedel Financial Consulting sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 22 shares — an estimated $1K sold.

Bedel Financial Consulting first reported a position in MYGN in Q3 2019 and held it in 10 quarters. The position peaked at $1K in Q4 2021. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

  • Bedel Financial Consulting reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 22 Myriad Genetics shares in Q1 2022, an estimated $1K.
  • Bedel Financial Consulting first reported a position in Myriad Genetics in Q3 2019 and held it in 10 quarters.
  • Bedel Financial Consulting's Myriad Genetics position peaked at $1K in Q4 2021.
  • 205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Bedel Financial Consulting's 13F filing for Q1 2022, filed 19 Apr 2022.